SWP
IOVA icon

Stratos Wealth Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Stratos Wealth Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,974
Closed -$267K – 1306
2021
Q4 		$267K Sell
13,974
-1,450
-9% -$31.9K 0.01% 1043
2021
Q3 		$380K Sell
15,424
-6,252
-29% -$147K 0.01% 862
2021
Q2 		$564K Sell
21,676
-27,165
-56% -$706K 0.01% 730
2021
Q1 		$1.55M Sell
48,841
-769
-2% -$31.9K 0.04% 376
2020
Q4 		$2.3M Buy
49,610
+8,298
+20% +$329K 0.07% 257
2020
Q3 		$1.36M Sell
41,312
-8,411
-17% -$258K 0.04% 324
2020
Q2 		$1.36M Sell
49,723
-15,864
-24% -$522K 0.05% 321
2020
Q1 		$1.96M Buy
+65,587
New +$1.74M 0.09% 222

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Stratos Wealth Partners's IOVA Position: Q1 2022 in Review

Stratos Wealth Partners sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 13,974 shares — an estimated $267K sold.

Stratos Wealth Partners first reported a position in IOVA in Q1 2020 and held it in 8 quarters. The position peaked at $2.3M in Q4 2020. 250 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

  • Stratos Wealth Partners reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Stratos Wealth Partners sold 13,974 Iovance Biotherapeutics shares in Q1 2022, an estimated $267K.
  • Stratos Wealth Partners first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 8 quarters.
  • Stratos Wealth Partners's Iovance Biotherapeutics position peaked at $2.3M in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Stratos Wealth Partners's 13F filing for Q1 2022, filed 26 Apr 2022.